STAMPEDE2, NCT06320067: A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer |
|
|
| Recruiting | 3 | 8000 | Europe | Stereotactic Ablative Body Radiotherapy (SABR), Stereotactic body radiotherapy (SBRT), 177Lu-PSMA-617, Lutetium (177Lu) Vipivotide Tetraxetan, AAA617, Pluvicto, Niraparib and Abiraterone Acetate Dual Action Tablet DAT, Nira-AA, CJNJ-67652000-ZZZ, Abiraterone Acetate, Zytiga, Apalutamide, Erleada, JNJ-56021927, Androgen Deprivation Therapy (ADT), Androgen Receptor Signalling Inhibitor (ARSI), Local Radiotherapy, Prednisolone, Docetaxel | University College, London, Cancer Research UK, Novartis, Janssen Pharmaceutica NV | Prostate Cancer Metastatic | 04/31 | 03/34 | | |
